-
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)
Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
IQGAP1 signaling review(Post)IQGAP1: IQ-motif containing GTPase-activating-like protein-1 reviewIQ motif-containing GTPase-activating-like protein-1 (IQGAP1) is a 190 KDa protein that belongs to a conserved family of sc
HMGB1 in inflammation and cancer(Post)HMGB1 Functional Overview High mobility group box 1 ( HMGB1), a member of the high-mobility group (HMG) family, was first identified in the thymus in 1973 an
Car t signalling pathway · H(Page) Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
Immunopeptidomics: Mapping the Hidden Landscape of the Cancer Immunome(Post)Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
What I learnt from meeting 1000+ researchers(Post)Over the past few years I have traversed through academia in a few different guises, first as a PhD student for about 5 years, then onto the traditional route of a post-doc, followed by a sales
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Inebilizumab: Advancing Research and Clinical Applications(Post)What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
Ionotropic Glutamate Receptors: Gateways to Neural Communication(Post)Ionotropic glutamate receptors (iGluRs) are pivotal in the fast excitatory synaptic transmission in the mammalian central nervous system (CNS). These receptors are not only crucial for normal brai
M2 Supplement for Organoid Cell Culture: Enhancing Growth and Differentiation(Post)The use of M2 Supplement in organoid culture has revolutionized the way researchers cultivate and maintain these three-dimensional (3D) cellular models. Organoids—self-organizing cell clu
Horseshoe Crab Blood and Endotoxin Testing: A Comprehensive Guide(Post)Horseshoe crabs, often referred to as "living fossils," are invaluable to modern medicine due to their unique blue blood. This blood is the source of Limulus Amebocyte Lysate (LAL), a sub
CB6 Biosimilar: Targeting SARS-CoV-2 with Cost-Effective Monoclonal Antibody Therapy(Post)CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind
Keep your Lab Book up to Date(Post)When PhDs and Post-Docs start in new lab they have the best intentions to keep their lab books up to date with notes, new research methods, data, and protocol information. These best efforts us
SITC 2024 - Scientific Programme, Venue & Exhibition(Post)SITC 2024: Meet Assay Genie at the Society for Immunotherapy of Cancer Annual MeetingAssay Genie is delighted to be attending and exhibiting at SITC 2024 in Houston, Texas on Friday the
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like